Thrombocytopenia - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 193

Thrombocytopenia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Thrombocytopenia - Pipeline Review, H1 2012', provides an overview of the Thrombocytopenia therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. 'Thrombocytopenia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thrombocytopenia.
- A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thrombocytopenia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Thrombocytopenia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Thrombocytopenia Therapeutic Products under Development, Key Players in Thrombocytopenia Therapeutics, Thrombocytopenia Pipeline Overview, Thrombocytopenia Pipeline, Thrombocytopenia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombocytopenia Overview
Therapeutics Development
An Overview of Pipeline Products for Thrombocytopenia
Thrombocytopenia Therapeutics under Development by Companies
Thrombocytopenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Thrombocytopenia Therapeutics – Products under Development by Companies
Thrombocytopenia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Thrombocytopenia Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
Shionogi & Co., Ltd.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Ablynx
Cangene Corporation
Symphogen A/S
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Octapharma AG
Ono Pharmaceutical Co., Ltd.
IMMUNOMEDICS, INC
Uni-Bio Science Group Ltd.
Protalex, Inc.
Maywufa Company Limited
AplaGen GmbH
Thrombotargets Corporation
Bolder Biotechnology, Inc.
Trillium Therapeutics Inc.
Bio Products Laboratory
SuppreMol GmbH
Viromed Co., Ltd.
aTyr Pharma, Inc.
Thrombocytopenia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Veltuzumab - Drug Profile
Nplate - Drug Profile
TT-173 - Drug Profile
E5501 - Drug Profile
Sym001 - Drug Profile
Revolade - Drug Profile
PRTX-100 - Drug Profile
ALX-0081 - Drug Profile
ALX-0681 - Drug Profile
S-888711 - Drug Profile
TTI-314 - Drug Profile
ThromboMer - Drug Profile
Alemtuzumab + Rituximab - Drug Profile
ONO-7746 - Drug Profile
PHN011 - Drug Profile
PHN012 - Drug Profile
PHN013 - Drug Profile
Sirolimus - Drug Profile
Rituxan + Cyclophosphamide + Vincristine + Prednisone - Drug Profile
Rituxan - Drug Profile
TXA127 - Drug Profile
Carboplatin + Cyclophosphamide + Etoposide + Etoposide Phosphate + Sodium Thiosulfate - Drug Profile
Mabthera - Drug Profile
Danazol - Drug Profile
Dexamethasone - Drug Profile
Prednisolone - Drug Profile
Dexamethasone - Drug Profile
Dexamethasone + MabThera - Drug Profile
Eltrombopag - Drug Profile
Dexamethasone - Drug Profile
Rituximab + Dexamethasone - Drug Profile
Gammaplex - Drug Profile
Prednisone - Drug Profile
Rituximab - Drug Profile
GSK 2285921 - Drug Profile
XAGRID - Drug Profile
R788 - Drug Profile
Gammagard - Drug Profile
Promacta - Drug Profile
Alemtuzumab + Busulfan + Cyclosporine + Fludarabine + Methotrexate + Methylprednisolone + Filgrastim + Stem Cell Transplantation - Drug Profile
Rituximab + Prednisone - Drug Profile
Anti-Thymocyte Globulin + Fludarabine + Thiotepa + T Cell Depleted Haplocompatible Peripheral Blood Transplantation + Radiation Therapy - Drug Profile
Mabthera - Drug Profile
Cyclosporine - Drug Profile
Cyclophosphamide + Etoposide phosphate + Carboplatin - Drug Profile
Carboplatin + Cyclophosphamide + Etoposide + Sodium Thiosulfate - Drug Profile
Eltrombopag + Stem Cell Transplantation + Total Body Irradiation - Drug Profile
Promacta - Drug Profile
SM101 - Drug Profile
Uniplas - Drug Profile
GBR 600 - Drug Profile
Romiplostim + Ribavirin + PEG-interferon alfa-2a - Drug Profile
Rituximab - Drug Profile
Alemtuzumab + Busulfan + Cyclosporine + Fludarabine Phosphate + Methotrexate + Methylprednisolone + Filgrastim + Bone Marrow Stem Cell Transplantation - Drug Profile
Anti-Thymocyte Globulin + Busulfan + Fludarabine Phosphate + Stem Cell Transplant + Radiation Therapy - Drug Profile
Eltrombopag + Azacitidine - Drug Profile
Anti-D - Drug Profile
NewGam - Drug Profile
Rituximab - Drug Profile
BBT-045 - Drug Profile
VM501 - Drug Profile
Umbilical Cord Blood Megakaryocyte Progenitor Cells - Drug Profile
IGIV3I Grifols - Drug Profile
Immune Globulin Intravenous Program - Drug Profile
Revolade - Drug Profile
PEG-VM501 - Drug Profile
Hematopoietic Stem Cell Transplantation - Drug Profile
Recombinant Human Thrombopoietin - Drug Profile
PanCyte - Drug Profile
UNI-rhIL-11 - Drug Profile
ALX-0081 + ALX-0681 - Drug Profile
Romiplostim - Drug Profile
Tmax - Drug Profile
Rituximab - Drug Profile
Thrombocytopenia Therapeutics – Drug Profile Updates
Thrombocytopenia Therapeutics – Discontinued Products
Thrombocytopenia Therapeutics - Dormant Products
Thrombocytopenia – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Thrombocytopenia, H1 2012
Products under Development for Thrombocytopenia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Shionogi & Co., Ltd., H1 2012
Amgen Inc., H1 2012
AstraZeneca PLC, H1 2012
GlaxoSmithKline plc, H1 2012
Ablynx, H1 2012
Cangene Corporation, H1 2012
Symphogen A/S, H1 2012
Eisai Co., Ltd., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Octapharma AG, H1 2012
Ono Pharmaceutical Co., Ltd., H1 2012
IMMUNOMEDICS, INC, H1 2012
Uni-Bio Science Group Ltd., H1 2012
Protalex, Inc., H1 2012
Maywufa Company Limited, H1 2012
AplaGen GmbH, H1 2012
Thrombotargets Corporation, H1 2012
Bolder Biotechnology, Inc., H1 2012
Trillium Therapeutics Inc., H1 2012
Bio Products Laboratory, H1 2012
SuppreMol GmbH, H1 2012
Viromed Co., Ltd., H1 2012
aTyr Pharma, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Thrombocytopenia Therapeutics – Drug Profile Updates
Thrombocytopenia Therapeutics – Discontinued Products
Thrombocytopenia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Thrombocytopenia, H1 2012
Products under Development for Thrombocytopenia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Chemotherapy Effects – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013